Sean Cao

Aureon Biosciences, Inc. designs and develops prognostic tests. The company’s prognostic tests include Prostate Px, which assists physicians as they counsel patients on the range of possible treatment options, as well as the patient’s probability of disease recurrence, disease progression and Post-Op Px, a prognostic test to provide patients and their physicians with information about treatment options. The company was founded by Robert H. Singer, Charles M. Cohen, Jonathan Edelson, Olivier Saidi and Carlos Cordón-Cardó in 2001 and is headquartered in Yonkers, NY.

New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group.

Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ.

CBC Group (Singapore) Pte. Ltd.(CBC Group) is a private equity firm founded in 2014 by Wei Fu. The firm is headquartered in Singapore with additional offices in New York, Hong Kong, Shanghai and Beijing and is wholly owned by CBC Group Investment Management Ltd.

NiKang Therapeutics, Inc. operates as biotechnology company. It focuses on developing novel small molecule oncology drug discovery. The company was founded by Zhenhai Gao and is headquartered in Wilmington, DE.

ENSEM Therapeutics, Inc. is a drug discovery and development company that specializes in developing small molecule precision medicines for oncology. The company is based in Waltham, MA. The company leverages its unique Kinetic Ensemble® platform to develop innovative drugs. The company has a potential oral CDK2 inhibitor, PI3K?, and a number of early-stage discovery programs at various stages of maturity launched with their Kinetic Ensemble® platform. ENSEM Therapeutics was founded by Shenfang Jin, Qi Zhang, Cheng Luo, and Shenfang Jin has been the CEO since incorporation.